Gleason grade progression is uncommon

Cancer Research

Volumn 73, Issue 16, 2013, Pages 5163-5168

  Penney, Kathryn L ^a   Stampfer, Meir J ^a   Jahn, Jaquelyn L ^a   Sinnott, Jennifer A ^a   Flavin, Richard ^b,d   Rider, Jennifer R ^a   Finn, Stephen ^b,d   Giovannucci, Edward ^a   Sesso, Howard D ^a   Loda, Massimo ^a,b,c   Mucci, Lorelei A ^a   Fiorentino, Michelangelo ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TRANSURETHRAL RESECTION;

EID: 84882581326     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0427     Document Type: Article

References (25)

1. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. Howwell does the Gleason score predict prostate cancer death? A 20- year follow up of a population based cohort in Sweden. J Urol 2006; 175:1337-40.
2. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason score and lethal prostate cancer: does 3 + 4 + 4 + 3? J Clin Oncol 2009;27:3459-64.
3. Choo R, Danjoux C, Morton G, Szumacher E, Sugar L, Gardner S, et al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 2007;67:1614-20.
4. Sheridan TB, Carter HB, Wang W, Landis PB, Epstein JI. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008;179:901-4; discussion 4-5.
5. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, et al. Changes in prostate cancer grade on serial biopsy inmen undergoing active surveillance. J Clin Oncol 2011;29:2795-800.
6. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.
7. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001;166:1688-91.
8. DraismaG,Etzioni R, Tsodikov A, Mariotto A, WeverE,GulatiR, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
9. Finne P, Fallah M, HakamaM, Ciatto S, Hugosson J, de Koning H, et al. Lead-time in the European randomised study of screening for prostate cancer. Eur J Cancer 2010;46:3102-8.
10. Savage CJ, Lilja H, Cronin AM, Ulmert D, Vickers AJ. Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate- specific antigen screening. Cancer Epidemiol Biomarkers Prev 2010;19:1201-7.
11. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006;175(3 Pt 1): 907-12.
12. Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH, et al. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int 2009;104: 1592-8.
13. Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi- Galluzzi C, et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 2004;22:300-6.
14. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999;17: 3167-72.
15. Falzarano SM, Magi-Galluzzi C. Prostate cancer staging and grading at radical prostatectomy over time. Adv Anat Pathol 2011;18: 159-64.
16. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97:1248-53.
17. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
18. Montironi R, Cheng L, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Mikuz G, et al. Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient's pathology and clinical reports. Eur Urol 2010;58:369-73.
19. Crawford ED. Epidemiology of prostate cancer. Urology 2003;62(6 Suppl 1):3-12.
20. Pashayan N, Pharoah P, Neal DE, Hamdy F, Donovan J, Martin RM, et al. Stage shift in PSA-detected prostate cancers-effect modification by Gleason score. J Med Screen 2009;16:98-101.
21. Draisma G, Postma R, Schroder FH, van der Kwast TH, de Koning HJ. Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 2006;119:2366-71.
22. Pashayan N, Pharoah P, Neal DE, Hamdy F, Donovan J, Martin RM, et al. PSA-detected prostate cancer and the potential for dedifferentiation- estimating the proportion capable of progression. Int J Cancer 2011;128:1462-70.
23. Sowalsky AG, Ye H, Bubley GJ, Balk SP. Clonal progression of prostate cancers from Gleason grade 3 to grade Cancer Res 2013; 73:1050-5.
24. Kovtun IV, Cheville JC, Murphy SJ, Johnson SH, Zarei S, Kosari F, et al. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res 2013;73:3275-84.
25. Lavery HJ, Droller MJ. Do Gleason patterns 3 and 4 prostate cancer represent separate disease states? J Urol 2012;188:1667-75.